Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 140, Issue 4, Pages 756-763Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2019.10.001
Keywords
-
Categories
Funding
- National Lottery, Belgium
- Foundation against Cancer, Belgium [2010-101]
- Fonds de la Recherche Scientifique - FNRS Equipment Grant [U.N035.17]
Ask authors/readers for more resources
Vascular malformations are subdivided into capillary, lymphatic, venous, arteriovenous, and mixed malformations, according to the type of affected vessels. Until a few years ago, treatment options were limited to sclerotherapy and/or surgery. Since, it has been demonstrated that the majority of vascular malformations are caused by inherited or somatic mutations in various genes. These mutations lead to hyperactivity of two major signaling pathways: the RAS/mitogen-activated protein kinase and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathways. These discoveries paved the way for the development and testing of targeted molecular inhibitors as therapies for vascular anomalies via repurposing of anticancer drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available